2022
Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET
Rossano S, Toyonaga T, Bini J, Nabulsi N, Ropchan J, Cai Z, Huang Y, Carson RE. Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET. EJNMMI Physics 2022, 9: 32. PMID: 35503134, PMCID: PMC9065222, DOI: 10.1186/s40658-022-00464-0.Peer-Reviewed Original ResearchFull spinal cordSpinal cord injuryHuman spinal cordSpinal cordAmyotrophic lateral sclerosisDistribution volume ratioCervical SCSynaptic densitySynaptic vesicle protein 2ACervical spinal cordBrain gray matterUse of PETBaseline VTWhole-body imagesSynapse lossCord injuryLateral sclerosisInjury severityGray matterNeurodegenerative disordersCordProtein 2AHuman dataDVR valuesCurrent standard
2020
Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand 11C-UCB-J
Bini J, Holden D, Fontaine K, Mulnix T, Lu Y, Matuskey D, Ropchan J, Nabulsi N, Huang Y, Carson RE. Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand 11C-UCB-J. EJNMMI Research 2020, 10: 83. PMID: 32666239, PMCID: PMC7359974, DOI: 10.1186/s13550-020-00670-w.Peer-Reviewed Original ResearchDose-limiting organUrinary bladderTime-activity curvesSynaptic densityOLINDA/EXM 1.0 softwareWhole-body PET scansWhole-body scanHuman adultsDose limitTotal radiation doseGastrointestinal tractPET scansHealthy adultsInjected activityRegion of interestLarge intestineNeuropsychiatric disordersEffective doseRelevant disordersBladderLiverRadiation doseAdultsMBqHigh uptake
2019
In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease
Toyonaga T, Smith LM, Finnema SJ, Gallezot JD, Naganawa M, Bini J, Mulnix T, Cai Z, Ropchan J, Huang Y, Strittmatter SM, Carson RE. In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. Journal Of Nuclear Medicine 2019, 60: 1780-1786. PMID: 31101744, PMCID: PMC6894376, DOI: 10.2967/jnumed.118.223867.Peer-Reviewed Original ResearchConceptsAPP/PS1 micePS1 miceAlzheimer's diseaseWT miceSynaptic densityC-UCBDrug washoutTreatment effectsPresenilin 1 (PS1) double transgenic miceHippocampal synaptic densityAPP/PS1Double transgenic miceEnd of treatmentWild-type miceAmyloid precursor proteinEarly Alzheimer's diseaseSignificant differencesSUVR-1New PET tracersMild cognitive impairmentAD miceSynaptic deficitsOral gavageAD treatmentHealthy subjects